VenoStent, Inc. is a clinical stage medical device and tissue engineering company founded in 2017. The company specializes in developing bioresorbable smart polymer scaffolds aimed at revolutionizing outcomes in vascular surgery. VenoStent recently received a significant $16.00M Series A investment on 31 July 2023, demonstrating strong investor confidence. The investment was led by a consortium of notable firms including Creative Ventures, Good Growth Capital, Cowtown Angels, Alumni Ventures Blockchain Fund, IAG Capital Partners, SNR, TMC Venture Fund, and Baylor Angel Network. With its focus on biotechnology and healthcare, VenoStent remains at the forefront of innovation in the United States, showcasing promising potential for disruption in the medical technology sector.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series A | $4.00M | 3 | 27 Jun 2024 | |
Grant | $3.60M | 1 | National Institutes of Health | 27 Jun 2024 |
Series A | $16.00M | 8 | TMC Venture Fund, Baylor Angel Network +1 | 31 Jul 2023 |
Seed Round | $3.00M | 8 | Olima Ventures | 23 Feb 2021 |
Seed Round | $150.00K | 1 | 25 Aug 2020 |